Is Marksans Pharma overvalued or undervalued?
As of September 11, 2025, Marksans Pharma is fairly valued with a PE ratio of 22.64 and an EV to EBITDA ratio of 15.05, showing strong ROCE at 21.42%, and is comparatively lower than some peers while its year-to-date stock performance has declined by 40.95%.
As of 11 September 2025, the valuation grade for Marksans Pharma has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. The PE ratio stands at 22.64, the EV to EBITDA ratio is 15.05, and the ROCE is a strong 21.42%. In comparison to its peers, Marksans Pharma's PE ratio is lower than Sun Pharma's 33.62 and Divi's Lab's 69.35, which are classified as expensive, while it is slightly higher than Cipla's attractive PE of 23.38. Additionally, the company's recent stock performance has been mixed, with a year-to-date return of -40.95%, contrasting with the Sensex's positive return of 4.36% over the same period. Overall, Marksans Pharma appears to be fairly valued in the current market context.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
